Watch the webcasts from our industry partners Satellite Symposia
TTFields: A potential innovative treatment modality in lung cancer
Novocure
- Welcome & objectives
F. Barlesi (Villejuif, France) L. Petruzelka (Prague, Czech Republic - What are TTFields - Mechanism of action and experiences in solid tumors
M. Proescholdt (Regensburg, Germany) - TTFields in malignant pleural mesothelioma (MPM) - The STELLAR trial
G. Ceresoli (Bergamo, Italy) - TTFields: A potential innovative treatment modality in lung cancer - The LUNAR trial and beyond
M. Cobo Dols (Malaga, Spain) - Live Q&A / discussion
L. Petruželka (Prague, Czech Republic) F. Barlesi (Villejuif, France) A. Speakers (Prague, Czech Republic)
Evolving treatment options and practices in EGFR-mutant NSCLC
Janssen Pharmaceutica
- Welcome and introductions
A. Passaro (Milan, Italy) E. Felip (Barcelona, Spain) - Unmet needs in the management of EGFR+ NSCLC
N. Leighl (Toronto, Canada) B. Besse (Villejuif, France) - Discussion - Unmet needs in the management of EGFR+ NSCLC
B. Besse (Villejuif, France) N. Leighl (Toronto, Canada) - Advances in the treatment of patients with EGFR exon20ins+ NSCLC
T. Mok (Sha Tin, Hong Kong PRC) A. Minchom (London, United Kingdom) - Discussion - Advances in the treatment of patients with EGFR exon20ins+ NSCLC
A. Minchom (London, United Kingdom) T. Mok (Sha Tin, Hong Kong PRC) - Live Q&A
E. Felip (Barcelona, Spain) A. Passaro (Milan, Italy) - Key learnings and closing remarks
A. Passaro (Milan, Italy) E. Felip (Barcelona, Spain)
Enabling future improvements in cancer care with fast next -generation sequencing (NGS) results
Thermo Fisher Scientific
- Introduction
N. Normanno (Napoli, Italy) - Complex biomarker driven therapy landscape in NSCLC and latest guidelines
F. Cappuzzo (Rome, Italy) - Molecular pathology - Meeting the challenges of a rapidly evolving biomarker landscape
J. Beasley (Birmingham, United Kingdom) - Removing barriers to routine NGS testing
P. Hofman (Nice, France) - Case studies and panel discussion - Leveraging fast NGS to potentially improve patient outcomes
Y. Wallis (Birmingham, United Kingdom) P. Hofman (Nice, France) N. Normanno (Napoli, Italy) F. Cappuzzo (Rome, Italy) - Audience Q&A
N. Normanno (Napoli, Italy)
Breaking barriers in thoracic cancers: The expanding possibilities for patients with I-O treatment
Bristol Myers Squibb
- Welcome & introductions
A. Scherpereel (Lille, France) - Is I-O treatment redefining survival for thoracic cancers?
A. Scherpereel (Lille, France) - The shifting treatment paradigm with I-O in resectable NSCLC
P. Forde (Baltimore, United States of America) - Understanding the potential for long-term survival with I-O in metastatic NSCLC
N. Reinmuth (Gauting, Germany) - Closing remarks & live Q&A
A. Scherpereel (Lille, France) - I-O as a new standard for patients with unresectable MPM
A. Scherpereel (Lille, France) - Closing remarks & live Q&A
A. Scherpereel (Lille, France) P. Forde (Baltimore, United States of America) N. Reinmuth (Gauting, Germany)